zacks.com / .zacks-com / Page 2

PATH's ARR increases from $1.46 billion in Q4 fiscal 2024 to $1.9 billion in Q1 fiscal 2027, highlighting resilient demand for AI-powered automation.

CLX's GOJO-led growth faces margin pressure, muted core demand and inflation risks, leaving investors focused on a durable recovery.

GEV's stronger guidance, backlog growth and AI-driven power demand give it the edge despite FLNC's cheaper valuation and data-center tailwinds.

Altria's pricing, margin gains and cash returns support earnings, but falling cigarette volumes and a premium to its median valuation keep the case balanced.

MO's Q2 earnings grow despite a miss, while a higher 2026 guidance floor puts more weight on pricing, margins and second-half execution.

Celestica (CLS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BROS raises its 2026 outlook after strong Q2 growth, with traffic and expansion supporting sales while rising costs remain a key risk.

BROS' strong traffic and unit growth face cost pressures, while the stock's pullback has improved its valuation without removing risks.

BROS' strong growth and transaction gains support its outlook, but a rich valuation and rising costs leave less room for execution errors.

Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.